GTC's Nasdaq listing at risk
This article was originally published in Scrip
Executive Summary
GTC Biotherapeutics' listing on the Nasdaq capital markets is under threat after its stock continued to trade below the minimum listing requirement of $35 million. Its stock has been trading below the requirement for the past 10 consecutive days and the US company has until June 15th to regain compliance.